WallStreetZenWallStreetZen

NASDAQ: ABOS
Acumen Pharmaceuticals Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for ABOS

Based on 2 analysts offering 12 month price targets for Acumen Pharmaceuticals Inc

Min Forecast
$8.00+253.98%
Avg Forecast
$8.00+253.98%
Max Forecast
$8.00+253.98%

Should I buy or sell ABOS stock?

Based on 2 analysts offering ratings for Acumen Pharmaceuticals Inc.

Strong Buy
Strong Buy
2 analysts 100%
Buy
0 analysts 0%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although ABOS's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates ABOS as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their ABOS stock forecasts and price targets.

ABOS stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-03-26
lockedlocked$00.00+00.00%2025-11-18

1 of 1

Forecast return on equity

Is ABOS forecast to generate an efficient return?

Company
N/A
Industry
69.79%
Market
179.49%

Forecast return on assets

Is ABOS forecast to generate an efficient return on assets?

Company
N/A
Industry
31.77%

ABOS earnings per share forecast

What is ABOS's earnings per share in the next 2 years based on estimates from 8 analysts?

Avg 1 year Forecast
-$1.68
Avg 2 year Forecast
-$1.49

ABOS revenue forecast

What is ABOS's revenue in the next 3 years based on estimates from 6 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$0.0
Avg 3 year Forecast
$0.0

ABOS vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
ABOS$2.26$8.00+253.98%Strong Buy
QSI$0.76$1.00+30.89%Hold
SGMT$4.89$26.00+431.70%Strong Buy
RNAC$5.85$34.00+481.20%Strong Buy
CRBP$8.71$47.00+439.61%Buy
View Top Biotech Stocks

Acumen Pharmaceuticals Stock Forecast FAQ

Is Acumen Pharmaceuticals Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: ABOS) stock is to Strong Buy ABOS stock.

Out of 2 analysts, 2 (100%) are recommending ABOS as a Strong Buy, 0 (0%) are recommending ABOS as a Buy, 0 (0%) are recommending ABOS as a Hold, 0 (0%) are recommending ABOS as a Sell, and 0 (0%) are recommending ABOS as a Strong Sell.

If you're new to stock investing, here's how to buy Acumen Pharmaceuticals stock.

What is ABOS's earnings growth forecast for 2026-2027?

(NASDAQ: ABOS) Acumen Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.92%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 35.94%.

Acumen Pharmaceuticals's earnings in 2026 is -$121,335,000.On average, 8 Wall Street analysts forecast ABOS's earnings for 2026 to be -$121,310,212, with the lowest ABOS earnings forecast at -$147,342,911, and the highest ABOS earnings forecast at -$65,208,120.

In 2027, ABOS is forecast to generate -$107,243,167 in earnings, with the lowest earnings forecast at -$131,629,415 and the highest earnings forecast at -$53,076,377.

What is ABOS's revenue growth forecast for 2026-2028?

(NASDAQ: ABOS) Acumen Pharmaceuticals's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.12%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.11%.

Acumen Pharmaceuticals's revenue in 2026 is $0.On average, 6 Wall Street analysts forecast ABOS's revenue for 2026 to be $0, with the lowest ABOS revenue forecast at $0, and the highest ABOS revenue forecast at $0. On average, 4 Wall Street analysts forecast ABOS's revenue for 2027 to be $0, with the lowest ABOS revenue forecast at $0, and the highest ABOS revenue forecast at $0.

In 2028, ABOS is forecast to generate $0 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $0.

What is ABOS's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: ABOS) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 31.77%.

What is ABOS's Price Target?

According to 2 Wall Street analysts that have issued a 1 year ABOS price target, the average ABOS price target is $8.00, with the highest ABOS stock price forecast at $8.00 and the lowest ABOS stock price forecast at $8.00.

On average, Wall Street analysts predict that Acumen Pharmaceuticals's share price could reach $8.00 by Mar 26, 2027. The average Acumen Pharmaceuticals stock price prediction forecasts a potential upside of 253.98% from the current ABOS share price of $2.26.

What is ABOS's Earnings Per Share (EPS) forecast for 2026-2027?

(NASDAQ: ABOS) Acumen Pharmaceuticals's current Earnings Per Share (EPS) is -$2.00. On average, analysts forecast that ABOS's EPS will be -$1.68 for 2026, with the lowest EPS forecast at -$2.04, and the highest EPS forecast at -$0.90. In 2027, ABOS's EPS is forecast to hit -$1.49 (min: -$1.82, max: -$0.74).

What is ABOS's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: ABOS) forecast ROE is N/A, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.